市场调查报告书
商品编码
1291598
癌症/肿瘤分析市场:2023-2028年全球行业趋势、份额、规模、增长、机会和预测Cancer/Tumor Profiling Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028 |
2022年,全球癌症/肿瘤分析市场规模达到104亿美元。展望未来,IMARC集团预计到2028年市场规模将达到184亿美元,在2023-2028年期间表现出9.8%的增长率(CAGR)。
癌症/肿瘤特征分析,也被称为生物标志物测试,是指用于识别肿瘤组织样本中特定蛋白质、基因或基因突变(变化)和其他生物标志物的实验室测试或程序。它协助肿瘤学家确定病人的肿瘤路径是否与现有的靶向治疗相匹配。它还有助于常规诊断、治疗决策,以及根据个人疾病的严重程度和基因组的积累为其制定个性化的治疗计划和疗法。癌症/肿瘤特征分析还在个性化医疗、研究、生物标志物的发现以及筛查和诊断技术的发展中得到了广泛的应用。
癌症/肿瘤特征分析被广泛用于肿瘤学研究和药物设计、发现和开发过程中的生物标志物的发现。因此,全球范围内癌症的广泛流行是推动市场增长的主要因素。除此之外,对诊断和肿瘤剖析的生物标志物的日益关注,以及大众对个性化医疗的偏好的转变,都增加了产品的需求。此外,政府对癌症研究的资助和支持显著增加,以开发先进技术,减少检测和识别肿瘤所需的时间。与此同时,分子生物学技术的最新进展,如下一代测序(NGS),正在加速癌症/肿瘤剖析的采用。此外,制药和生物技术公司为推出新型疗法和新的药物设计技术而在研究和开发(R&D)活动中的投资不断增加,正在推动市场增长。其他因素,包括不断增加的临床试验,越来越多地采用免疫测定技术,有利的报销政策,不断改善的医疗基础设施,以及技术进步,也为市场创造了积极的前景。
The global cancer/tumor profiling market size reached US$ 10.4 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 18.4 Billion by 2028, exhibiting a growth rate (CAGR) of 9.8% during 2023-2028.
Cancer/tumor profiling, also known as biomarker testing, refers to a laboratory test or procedure used to identify specific proteins, genes or gene mutations (changes) and other biomarkers in a tumor tissue sample. It assists oncologists in determining if the pathways of a patient's tumor match up with the available targeted therapies. It also aids in routine diagnostics, therapeutic decision-making, and developing personalized treatment plans and therapies for individuals based on the severity of their ailment and genomic build-up. Cancer/tumor profiling also finds extensive applications in personalized medicine, research, the discovery of biomarkers, and the development of screening and diagnostic techniques.
Cancer/tumor profiling is widely used in oncology research and discovery of biomarkers during the process of drug design, discovery and development. As a result, the widespread prevalence of cancer across the globe represents the primary factor driving the market growth. Besides this, the growing focus on biomarkers for diagnosis and tumor profiling and the shifting preferences toward personalized medicine among the masses are augmenting the product demand. Additionally, there has been a significant rise in government funding and support for cancer research for the development of advanced techniques to reduce the time taken for the detection and identification of tumors. Along with this, the recent advancements in molecular biology techniques, such as next-generation sequencing (NGS), are accelerating the adoption of cancer/tumor profiling. Furthermore, the increasing investments by pharmaceutical and biotechnology companies in research and development (R&D) activities for the launch of novel therapies and new drug designing techniques are propelling the market growth. Other factors, including the rising number of clinical trials, growing adoption of immunoassay techniques, favorable reimbursement policies, improving healthcare infrastructure, and technological advancements, are also creating a positive outlook for the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global cancer/tumor profiling market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on cancer type, technology, technique and application.
Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Melanoma Cancer
Others
Next-Generation Sequencing (NGS)
Polymerase Chain Reaction (PCR)
Immunohistochemistry (IHC)
In-Situ Hybridization (ISH)
Microarray
Others
Genomics
Proteomics
Epigenetics
Metabolomics
Personalized Medicine
Diagnostics
Biomarker Discovery
Prognostics
Others
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Becton Dickinson and Company, Caris Life Sciences, Exact Sciences Corporation, F. Hoffmann-La Roche Ltd, Hologic Inc., HTG Molecular Diagnostics Inc., Illumina Inc., Laboratory Corporation of America Holdings, NeoGenomics Laboratories, Qiagen N.V., Siemens AG and Sysmex Corporation.
Key Questions Answered in This Report
1. What was the size of the global cancer/tumor profiling market in 2022?
2. What is the expected growth rate of the global cancer/tumor profiling market during 2023-2028?
3. What has been the impact of COVID-19 on the global cancer/tumor profiling market?
4. What are the key factors driving the global cancer/tumor profiling market?
5. What is the breakup of the global cancer/tumor profiling market based on the cancer type?
6. What is the breakup of the global cancer/tumor profiling market based on the technique?
7. What are the key regions in the global cancer/tumor profiling market?
8. Who are the key players/companies in the global cancer/tumor profiling market?